Volume 3.46 | Nov 22

Mesenchymal Cell News 3.46, November 22, 2011
     In this issue: Publications Industry News | Policy News | Events | Jobs 
Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter
TOP STORY
Mesenchymal Stem Cell–Based Tissue Regeneration Is Governed by Recipient T Lymphocytes via Interferon γ and Tumor Necrosis Factor α
Here researchers show that proinflammatory T cells inhibit the ability of exogenously added bone marrow mesenchymal stem cells to mediate bone repair. [Nat Med] Abstract | Press Release

Got Paper? Get StemLab™. Schedule Your Demo
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Mesenchymal Stromal Cell Mutations and Wound Healing Contribute to the Etiology of Desmoid Tumors
Researchers hypothesized that desmoid tumors may arise in familial adenomatous polyposis coli patients after mesencyhmal stromal cells acquire somatic mutations during the proliferative phase of wound healing. [Cancer Res] Abstract

Synergistic Control of Mesenchymal Stem Cell Differentiation by Nanoscale Surface Geometry and Immobilized Growth Factors on TiO2 Nanotubes
The aim of this study is to elucidate whether combined environmental signals provided by nanoscale topography and by growth factors control cell behavior of mesenchymal stem cells in a synergistic or simply additive manner. [Small] Abstract

ß-PIX Is Critical for Transplanted Mesenchymal Stromal Cell Migration
Researchers suggest that transplantation of allogeneic or genetically modified autologous stem cells might be a more promising strategy for amyotrophic lateral sclerosis patients than transplantation of autologous stem cells. [Stem Cells Dev] Abstract

Differential Signaling through ALK-1 and ALK-5 Regulates Leptin Expression in Mesenchymal Stem Cells
Here, researchers investigated leptin expression in mesenchymal stem cells from bone marrow and cord matrix. [Stem Cells Dev] Abstract

Differentiation of Induced Pluripotent Stem Cells into Dental Mesenchymal Cells
Here researchers demonstrated that neural crest-like cells derived from mouse induced pluripotent stem cells have the potential to differentiate into odontogenic mesenchymal cells. [Stem Cells Dev] Abstract

Modulation of Human Mesenchymal Stem Cell Function in a Three-Dimensional Matrix Promotes Attenuation of Adverse Remodeling after Myocardial Infarction
Researchers hypothesized that human mesenchymal stem cells applied to the heart in a collagen matrix would outperform the same cells grown in a monolayer and directly injected for cardiac cell replacement after myocardial infarction in a rat model. [J Tissue Eng Regen Med] Abstract

Cartilage Oligomeric Matrix Protein Enhances Matrix Assembly during Chondrogenesis of Human Mesenchymal Stem Cells
To test the hypothesis that cartilage oligomeric matrix protein (COMP)/thrombospondin-5 functions in the assembly of the extracellular matrix during cartilage morphogenesis, researchers have employed mesenchymal stem cell chondrogenesis in vitro as a model to examine the effects of COMP over-expression on neo-cartilage formation. [J Cell Biochem] Abstract

Analysis of the Effects of HIV-1 Tat on the Survival and Differentiation of Vessel Wall-Derived Mesenchymal Stem Cells
As vessel wall mesenchymal stem cells (MSCs) are involved in the regulation of vessel structure homeostasis, researchers investigated the role of Tat, a key factor in HIV replication and pathogenesis, in MSC survival and differentiation. [J Cell Biochem] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response

INDUSTRY NEWS

Positive Outcome from FDA Meeting for Type II Diabetes Clinical Program Using Intravenous Delivery of Mesoblast’s Proprietary Adult Stem Cells
Mesoblast Limited announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company’s first clinical trial using intravenous delivery of its proprietary allogeneic mesenchymal precursor cell technology in patients with Type II Diabetes. [Mesoblast Limited] Press Release

MSRCNY Receives Approval for Groundbreaking Stem Cell Trial in Multiple Sclerosis
The Multiple Sclerosis Research Center of New York (MSRCNY) and the International Cellular Medicine Society (ICMS) jointly announced the ICMS Institutional Review Board’s approval of the first study to use autologous brain-like or neural stem cells for multiple sclerosis. [International Multiple Sclerosis Management Practice] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW MRC Centre for Regenerative Medicine – Driving Stem Cell Research Towards Therapy
May 12-22, 2012
Edinburgh, Scotland

Visit
our events page to see a complete list of events in the mesenchymal cell community.
JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Mesenchymal Stem Cells & Scaffolds Fellowship (Università degli Studi di Genova)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mesenchymal Cell News: Archives | Events | Contact Us